Dr.  Vicente Soriano, MD, PhD - UNIR Health Sciences School - Professor

Dr. Vicente Soriano

MD, PhD

UNIR Health Sciences School

Professor

Madrid, Madrid | Spain

Main Specialties: Hepatology, Infectious Disease, Medical Genetics

Additional Specialties: Infectious Diseases

ORCID logohttps://orcid.org/0000-0002-4624-5199


Top Author

Dr.  Vicente Soriano, MD, PhD - UNIR Health Sciences School - Professor

Dr. Vicente Soriano

MD, PhD

Introduction

Vicente Soriano, MD, PhD, received his medical degree in Barcelona, Spain, where he subsequently conducted his specialty training on internal medicine. After completing a post-doctoral stage at the CBER, FDA in Bethesda (USA), he returned to Spain and joined the Department of Infectious Diseases at Hospital Carlos III in Madrid. He became the assistant director since 1999. His expertise has focused mainly on viral infections, specifically HIV and viral hepatitis. More recently his area of interest expand to human genomics.
Dr. Soriano is the editor-in-chief of AIDS Reviews, an international, peer-reviewed journal focused on HIV research (impact factor ?4). His team has produced more than 900 publications in international journals (PubMed) and currently is ranked within the first 10 worldwide in terms of impact factor in scientific publications in the field of HIV infection (www.aidshivresearch.com).
Chair of the International Hepatitis & HIV Coinfection Panel, Dr. Soriano is assisting the National AIDS Program in Spain and is the editor of Manual del SIDA, a reference textbook of HIV/AIDS for Spanish-speaking countries. He has been advisor for WHO and the European Commission. More recently he became professor at the UNIR Health Sciences School.

Primary Affiliation: UNIR Health Sciences School - Madrid, Madrid , Spain

Specialties:

Additional Specialties:

Research Interests:


View Dr. Vicente Soriano’s Resume / CV

Education

Nov 1992
CBER, FDA, Bethesda
Post-doc
Virology
Sep 1980 - Jan 1986
Medical School, Autonomous University
Professor
Infectious Diseases
Sep 1980 - Jan 1986
Medical School, Autonomous University Barcelona
Professor
Infectious Diseases

Experience

Jan 2018 - Jan 2018
UNIR-Madrid, Universidad Internacional de La Rioja
Professor
Facultad Ciencias de la Salud
Apr 2015 - May 2014
Hospital Universitario La Paz, Madrid
Consultant
Infectious Diseases
Apr 2015 - Jun 1992
Hospital Carlos III, Madrid
Assistant Director
Infectious Diseases
Jan 2018
Universidad Internacional de La Rioja
Apr 2015
Hospital Universitario La Paz
Consultant
Infectious Diseases

Publications

2008Publications

4423Reads

4Profile Views

324PubMed Central Citations

Decline and changing profile of hepatitis delta among injection drug users in Spain.

Antivir Ther 2018 ;23(1):87-90

Infectious Diseases Unit, La Paz University Hospital & Autonomous University, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3851/IMP3161DOI Listing
September 2019
154 Reads
3.020 Impact Factor

Should HIV Patients be concerned about Occult Hepatitis B?

AIDS Rev 2018;20(4):238-239

UNIR Health Sciences School and La Paz University Hospital Madrid, Spain.

View Article

Download full-text PDF

Source
May 2019
4 Reads
3.787 Impact Factor

Hepatitis Delta Could Be More Frequent than Previously Thought.

AIDS Rev 2018;20(4):236

UNIR Health Sciences School and La Paz University Hospital Madrid, Spain.

View Article

Download full-text PDF

Source
May 2019
9 Reads
3.787 Impact Factor

Longer Life Expectancy but still Accelerating Aging in HIV Patients under Antiretroviral Therapy.

AIDS Rev 2018;20(4):236a-237

UNIR Health Sciences School Madrid, Spain.

View Article

Download full-text PDF

Source
May 2019
5 Reads
3.787 Impact Factor

HIV co-infection in HTLV-1 carriers in Spain.

Virus research

BACKGROUND:Human retroviruses HIV and HTLV share transmission routes. HIV widely spread in Spain during the 80 s through injection drug use and sex, and nowadays HIV rates in Spain account for one of the largest in Europe. In contrast, HTLV-1 is not endemic in Spain, despite hosting huge numbers of migrants from highly endemic regions. Herein, we report the rate and main features of the HIV-HTLV co-infected population in Spain. METHODS:A national registry exists in Spain for HTLV since year 1989. Data from standardized case report forms and one centralized lab repository were reviewed, especially for the subset with HTLV-HIV co-infection. RESULTS:Up to December 2018, a total of 369 individuals with HTLV-1 had been diagnosed in Spain. 64% of the population were females, and Latin American individuals accounted for 64.5%. Classical HTLV-associated illnesses were found in 12.7% (myelopathy) and 7.6% (leukemia). HIV coinfection was found in 12 (3.2%). Of those, 3 patients (25%) were female and 39 (75%) were of non-Spanish origin. All but two harbored HIV-1 subtype B, being non-B variants found in the two West Africans. Exposure had been sexual in most cases, being 4 homosexual men. Seven HTLV-HIV co-infected patients had developed AIDS and two had developed myelopathy. There was no evidence for increased HTLV-1 clinical pathogenicity due to HIV coinfection. CONCLUSION:HIV coinfection is infrequent (<5%) among HTLV-1 carriers in Spain. More than half of co-infected patients come from Latin America. Sexual contact is the most frequent risk behavior, being MSM one third of cases. Late diagnosis explains the high rate (9/12) of clinical manifestations in our HIV-HTLV co-infected population.

https://doi.org/10.1016/j.virusres.2019.04.004

View Article
April 2019
9 Reads

Occult hepatitis B and HIV infection.

European journal of gastroenterology & hepatology

INTRODUCTION:Occult hepatitis B virus (HBV) infection, so-called occult B infection (OBI), is defined by the recognition of HBV-DNA in the absence of serum hepatitis B surface antigen (HBsAg). The HBV-DNA genome in OBI is fully replication competent and produced in the liver, characteristically with low-level HBV-DNA fluctuations in the bloodstream. The OBI status remains between chronic (HBsAg+) and resolved (anti-HBs+) phases in the natural history of HBV infection. METHODS:The clinical interest in OBI has increased because of its potential for overt HBV reactivation under immunosuppression as well as for HBV transmission, well established in recipients of blood transfusions and/or organ transplants. RESULTS:Given the shared transmission routes for HIV and HBV, earlier reports claimed that OBI was more frequent in AIDS patients. By contrast, the current scenario shows that OBI is negligible in the HIV population. One explanation is that HBV immunization and recall vaccination campaigns have been very active in this group. A second and most important reason points to the wide use of antiretroviral regimens that include anti-HBV active agents, that is, tenofovir, lamivudine, and/or emtricitabine. They are recommended either as treatment for all HIV carriers or as pre-exposure prophylaxis for uninfected individuals at risk. The consequences are that HBV reactivations associated with HIV-related immunodeficiency have become very rare. Furthermore, HBV suppression with these antivirals has markedly reduced the likelihood of transmission from OBI carriers and/or acquisition by uninfected exposed individuals. CONCLUSION:Enthusiasm unabated, new tenofovir-sparing antiretroviral regimens are becoming popular and might account for a resurgence of OBI in the HIV setting.

https://doi.org/10.1097/MEG.0000000000001417

View Article
April 2019
9 Reads

Hepatitis delta estimates in the United States revisited.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

https://doi.org/10.1093/cid/ciz271

View Article
April 2019
10 Reads

Clinical experience with integrase inhibitors in HIV-2-infected individuals in Spain.

The Journal of antimicrobial chemotherapy

Background:HIV-2 is a neglected virus despite estimates of 1-2 million people being infected worldwide. The virus is naturally resistant to some antiretrovirals used to treat HIV-1 and therapeutic options are limited for patients with HIV-2. Methods:In this retrospective observational study, we analysed all HIV-2-infected individuals treated with integrase strand transfer inhibitors (INSTIs) recorded in the Spanish HIV-2 cohort. Demographics, treatment modalities, laboratory values, quantitative HIV-2 RNA and CD4 counts as well as drug resistance were analysed. Results:From a total of 354 HIV-2-infected patients recruited by the Spanish HIV-2 cohort as of December 2017, INSTIs had been given to 44, in 18 as first-line therapy and in 26 after failing other antiretroviral regimens. After a median follow-up of 13 months of INSTI-based therapy, undetectable viraemia for HIV-2 was achieved in 89% of treatment-naive and in 65.4% of treatment-experienced patients. In parallel, CD4 gains were 82 and 126 cells/mm3, respectively. Treatment failure occurred in 15 patients, 2 being treatment-naive and 13 treatment-experienced. INSTI resistance changes were recognized in 12 patients: N155H (5), Q148H/R (3), Y143C/G (3) and R263K (1). Conclusions:Combinations based on INSTIs are effective and safe treatment options for HIV-2-infected individuals. However, resistance mutations to INSTIs are selected frequently in failing patients, reducing the already limited treatment options.

https://doi.org/10.1093/jac/dkz007

View Article
March 2019
10 Reads

Hot News: HTLV-1 Infection Still A Neglected Disease

Authors:
Vicente Soriano

AIDS Rev 2018;20(3):175

UNIR Health Sciences School and La Paz University Hospital Madrid, Spain.

View Article

Download full-text PDF

Source
February 2019
36 Reads
3.787 Impact Factor

Predictors of Hepatitis C Treatment Failure After Using Direct-Acting Antivirals in People Living With Human Immunodeficiency Virus.

Open forum infectious diseases

Background:Little is known about the influence of ongoing barriers to care in the persistence of hepatitis C virus (HCV) viremia after treatment with direct-acting antivirals (DAAs) among people living with human immunodeficiency virus (PLWH). Methods:We conducted a retrospective cohort analysis of PLWH treated through the standard of care in 3 Western countries, to investigate the predictors of HCV treatment failure (clinical or virologic), defined as having a detectable serum HCV ribonucleic acid within 12 weeks after DAA discontinuation. In addition to HCV and liver-related predictors, we collected data on ongoing illicit drug use, alcohol abuse, mental illness, and unstable housing. Logistic regression analyses were used to identify predictors of HCV treatment failure. Results:Between January 2014 and December 2017, 784 PLWH were treated with DAA, 7% (n = 55) of whom failed HCV therapy: 50.9% (n = 28) had a clinical failure (discontinued DAA therapy prematurely, died, or were lost to follow-up), 47.3% (n = 26) had an HCV virologic failure, and 1 (1.8%) was reinfected with HCV. Ongoing drug use (odds ratio [OR] = 2.60) and mental illness (OR = 2.85) were independent predictors of any HCV treatment failure. Having both present explained 20% of the risk of any HCV treatment failure due to their interaction (OR = 7.47; P < .0001). Predictors of HCV virologic failure were ongoing illicit drug use (OR = 2.75) and advanced liver fibrosis (OR = 2.29). Conclusions:People living with human immunodeficiency virus with ongoing illicit drug use, mental illness, and advanced liver fibrosis might benefit from enhanced DAA treatment strategies to reduce the risk of HCV treatment failure.

http://europepmc.org/articles/PMC6440685

View Article
February 2019
8 Reads

Clinical Presentation of Individuals With Human T-Cell Leukemia Virus Type-1 Infection in Spain.

Open forum infectious diseases

Background:Although only 8%-10% of persons infected with human T-cell leukemia virus type 1 (HTLV-1) may develop virus-associated diseases lifelong, misdiagnosis of asymptomatic infected carriers frequently leads to late diagnoses. Methods:A nationwide HTLV-1 register was created in Spain in 1989. A total of 351 infected persons had been reported by the end of 2017. We examined all new HTLV-1 diagnoses during the last decade and compared their clinical presentation. Results:A total of 247 individuals with HTLV-1 infection had been reported in Spain since year 2008. The incidence has remained stable with 20-25 new diagnoses yearly. Women represented 62%. Only 12% were native Spaniards, most of whom were foreigners from Latin America (72.5%). Up to 57 (23%) individuals presented clinically with HTLV-1-associated conditions, including subacute myelopathy (n = 24; 42.1%), T-cell lymphoma (n = 19; 33.3%), or Strongyloides stercoralis infestation (n = 8; 14%). Human T-cell leukemia virus type 1 diagnosis had been made either at blood banks (n = 109; 44%) or at clinics (n = 138; 56%). It is interesting to note that Spaniards and especially Africans were overrepresented among patients presenting with HTLV-1-associated illnesses, suggesting that misdiagnosis and late presentation are more frequent in these populations compared to Latin Americans. Conclusions:Given that 23% of new HTLV-1 diagnoses in Spain are symptomatic, underdiagnosis must be common. Although screening in blood banks mostly identifies asymptomatic Latin American carriers, a disproportionately high number of Spaniards and Africans are unveiled too late, that is, they already suffer from classic HTLV-1 illnesses.

http://europepmc.org/articles/PMC6386801

View Article
January 2019
11 Reads

Author Correction: Telomere length and survival in primary cutaneous melanoma patients.

Scientific reports

A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has been fixed in the paper.

http://europepmc.org/articles/PMC6294772

View Article
December 2018
8 Reads

Hot News: Hepatitis B Gene Therapy Coming to Age.

Authors:
Vicente Soriano

AIDS Rev 2018 Apr-Jun;20(2):125-127

La Paz University Hospital and UNIR Health Sciences School, Madrid, Spain.

View Article

Download full-text PDF

Source
October 2018
55 Reads
3.790 Impact Factor

Report from the International Conference on Viral Hepatitis - 2017.

AIDS Rev 2018 Jan-Mar;20(1):58-70

Liver Unit, Rush University Medical Center, Chicago, IL, USA.

View Article

Download full-text PDF

Source
October 2018
15 Reads
3.790 Impact Factor

TERT promoter mutation subtypes and survival in stage I and II melanoma patients.

International journal of cancer

Mutations within the promoter of gene encoding telomerase reverse transcriptase subunit are frequent in many cancers including melanoma. Previously, the TERT promoter mutations were shown to associate with markers of poor outcome and reduced survival in patients with primary melanoma. In this study, we investigated the impact of the subtypes of TERT mutations on disease-free and melanoma-specific survival in 287 patients with stage I/II nonacral melanoma. Our results showed that of the three TERT promoter mutation subtypes, in multivariate models, the -138/-139 CC > TT tandem mutation associated with worst disease-free and melanoma-specific survival. In particular, in combination with BRAF/NRAS mutations, the -138/-139 CC > TT TERT promoter mutation associated with statistically significant poor disease-free and melanoma-specific survival with hazard ratios of 6.04 (95% CI 2.03-17.94, p = 0.001) and 12.59 (95% CI 2.18-72.70, p = 0.005), respectively. In contrast to the survival data, luciferase assays showed that the highest activity was observed in experiments with a promoter construct with -124 C > T mutation followed by the -138/-139 CC > TT and -146 C > T mutations, which showed similar activity. Based on previous reports, we speculate that the tandem mutation probably leads to greater genomic instability than the common TERT promoter mutations, hence the association with worst survival. However, the results from the study are only preliminary with limited patient data, therefore, require a cautious interpretation. The observations in this study, if confirmed, could have implications for melanoma patients treated with MAP-kinase inhibitors.

https://doi.org/10.1002/ijc.31780

View Article
October 2018
9 Reads

Prevalence and incidence of hepatitis delta in patients with chronic hepatitis B in Spain.

Eur J Gastroenterol Hepatol 2018 09;30(9):1060-1062

Infectious Diseases Unit, La Paz University Hospital.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MEG.0000000000001163DOI Listing
September 2018
22 Reads
2.152 Impact Factor

Impact of ITPA gene polymorphisms on the risk of ribavirin-induced haemolytic anaemia using interferon-free antivirals for chronic hepatitis C.

Antivir Ther 2017 15;22(7):571-575. Epub 2017 Feb 15.

Department of Internal Medicine & Liver Transplantation Unit, Puerta de Hierro Research Institute & University Hospital, Majadahonda, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3851/IMP3138DOI Listing
July 2018
33 Reads
2 Citations
3.020 Impact Factor

Telomere length and survival in primary cutaneous melanoma patients.

Scientific reports

Telomere repeats at chromosomal ends, critical to genomic integrity, undergo age-dependent attrition. Telomere length, a polygenic trait, has been associated with risk of several disorders including cancers. In contrast to association of long telomeres with increased risk of several cancers, including melanoma, emerging reports suggest that short telomeres predict poor survival in patients with different cancers. In this study based on 1019 stage I and II cutaneous melanoma patients, we show an association between the patients with short telomeres and poor melanoma-specific survival (HR 2.05, 95% CI 1.33-3.16) compared to patients with long telomeres. Due to inverse correlation between age and telomere length (r -0.19, P < 0.0001), we stratified the patients into quantiles based on age at diagnosis and also carried out age-matched analysis. The effect of short telomeres on survival was determined by using multivariate Cox regression that included composite genetic risk score computed from genotyping of the patients for telomere-length associated polymorphisms. The effect of decreased telomere length on poor melanoma-specific survival was particularly strong in patients within the age quantile below 30 years (HR 3.82, 95% CI 1.10-13.30) and between 30-40 years (HR 2.69, 95% CI 1.03-7.03). Our study shows that in contrast to increased melanoma risk associated with increased telomere length, decreased telomere length predicts poor survival in melanoma subgroups.

http://europepmc.org/articles/PMC6053393

View Article
July 2018
9 Reads

Hot News: Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.

Authors:
Vicente Soriano

AIDS Rev 2017 Oct-Dec;19(3):167-172

Infectious Diseases Unit, La Paz University Hospital, Madrid, Spain.

View Article

Download full-text PDF

Source
June 2018
102 Reads
3.790 Impact Factor

Rate and predictors of treatment failure to all-oral HCV regimens outside clinical trials.

Antivir Ther 2017 24;22(4):307-312. Epub 2016 Jun 24.

Department of Internal Medicine, Puerta de Hierro Research Institute & University Hospital, Majadahonda, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3851/IMP3061DOI Listing
May 2018
80 Reads
7 Citations
3.020 Impact Factor

AIDS Clinical Research in Spain-Large HIV Population, Geniality of Doctors, and Missing Opportunities.

Viruses 2018 05 30;10(6). Epub 2018 May 30.

Department of Infectious Diseases, University Hospital Crosshouse, Kilmarnock KA2 0BE, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/v10060293DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6024378PMC
May 2018
38 Reads
1 Citation
3.280 Impact Factor

Treatment and prevention of HIV infection with long-acting antiretrovirals.

Expert Rev Clin Pharmacol 2018 May 29;11(5):507-517. Epub 2018 Mar 29.

b Laboratory of Internal Medicine , Puerta de Hierro Research Institute , Majadahonda , Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17512433.2018.1453805DOI Listing
May 2018
38 Reads

Prevention of liver cancer with new curative hepatitis C antivirals: Real-world challenges.

Cancer 2018 04 27;124(8):1647-1649. Epub 2018 Feb 27.

Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31291DOI Listing
April 2018
8 Reads
1 Citation
4.890 Impact Factor

Hepatitis A Outbreaks in European Homosexual Men.

AIDS Rev 2017 Apr - Jun;19(2):113-114

La Paz University Hospital, Madrid, Spain.

View Article

Download full-text PDF

Source
February 2018
20 Reads
1 Citation
3.790 Impact Factor

A New HIV Paradigm: Dual Antiretroviral Regimens as Maintenance Therapy.

AIDS Rev 2017 Apr - Jun;19(2):113-114

La Paz University Hospital, Autonomous University, Madrid, Spain.

View Article

Download full-text PDF

Source
February 2018
21 Reads
1 Citation
3.790 Impact Factor

Rebound in Sexually Transmitted Infections Following the Success of Antiretrovirals for HIV/AIDS.

AIDS reviews

Nearly 1 million people become infected every day with any of the four major curable sexually transmitted infections (STIs), namely trichomoniasis, chlamydia, gonorrhea, and syphilis. Despite huge global incidence, STIs remain as neglected diseases. The success of antiretrovirals for halting progression to AIDS in HIV-infected individuals and for stopping HIV transmission to uninfected contacts, either as pre- or post-exposure -prophylaxis, has to lead to increased risky sexual behaviors through risk compensation. Recent epidemics and outbreaks of STIs among men having sex with men reflect the global loss of fear to HIV/AIDS. The -alarming rising rates of STIs worldwide have been fueled by: (1) rapid spread of drug resistance, that is, for Neisseria gonorrhoeae and Mycoplasma genitalium; (2) unprecedented impact of recreational drugs (chemsex) and internet (apps, websites) for facilitating exposure to multiple sex partners; and (3) growing rates of sexual violence and commercial sex, associated with wars, refugees, migrations, traveling, and sexual tourism. Moreover, there is an increasing appreciation of sexual transmission for other agents, -including human T-lymphotropic virus type 1, hepatitis A and C viruses, Zika, and Ebola. For addressing this new scenario for STIs, an expert panel workshop was arranged in Madrid, Spain in May 2018. This review summarizes the discussions at the meeting.

https://doi.org/10.24875/AIDSRev.18000034

View Article
January 2018
9 Reads

High serum HCV RNA in chronic hepatitis C patients coinfected with HIV despite successful antiretroviral therapy.

Antivir Ther 2016 18;21(6):489-494. Epub 2016 Feb 18.

Infectious Diseases Unit, La Paz University Hospital, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3851/IMP3038DOI Listing
January 2018
25 Reads
2 Citations
3.020 Impact Factor

Is Ribavirin Teratogenic in Humans? No Evidence So Far.

Drug Saf 2017 12;40(12):1163-1165

Infectious Diseases Unit, La Paz University Hospital and Medical School, Autonomous University, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40264-017-0597-zDOI Listing
December 2017
16 Reads
2.824 Impact Factor

Need to Face Liver Cirrhosis after HCV Cure with Antivirals.

EBioMedicine 2017 10 25;24:24-25. Epub 2017 Aug 25.

Liver Transplantation Unit, Internal Medicine Department, Puerta de Hierro Research Institute, Majadahonda, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ebiom.2017.08.022DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651974PMC
October 2017
19 Reads
1 Citation

Evaluation of sofosbuvir, velpatasvir plus voxilaprevir as fixed-dose co-formulation for treating hepatitis C.

Expert Opin Drug Metab Toxicol 2017 Sep 28;13(9):1015-1022. Epub 2017 Jul 28.

b Department of Internal Medicine , Puerta de Hierro Research Institute , Majadahonda , Spain.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17425255.2017.1
Publisher Site
http://dx.doi.org/10.1080/17425255.2017.1359254DOI Listing
September 2017
142 Reads
2 Citations
2.831 Impact Factor

Drug interactions in HIV-infected patients treated for hepatitis C.

Expert Opin Drug Metab Toxicol 2017 Aug 13;13(8):807-816. Epub 2017 Jul 13.

a Infectious Diseases Unit , La Paz University Hospital , Madrid , Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17425255.2017.1351942DOI Listing
August 2017
34 Reads
1 Citation
2.831 Impact Factor

Dual antiretroviral therapy for HIV infection.

Expert Opin Drug Saf 2017 Aug 11;16(8):923-932. Epub 2017 Jul 11.

d Internal Medicine Department , Nuestra Señora de la Paz Hospital , Madrid , Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14740338.2017.1343300DOI Listing
August 2017
35 Reads
1 Citation
2.911 Impact Factor

Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response.

J Antimicrob Chemother 2017 07;72(7):2083-2088

Puerta de Hierro University Hospital, Majadahonda, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jac/dkx090DOI Listing
July 2017
27 Reads
1 Citation
5.313 Impact Factor

Human T-lymphotropic virus type 1 infection and disease in Spain.

AIDS 2017 07;31(12):1653-1663

aPuerta de Hierro Research Institute, Majadahonda, Madrid bHospital Vall d'Hebrón, Barcelona cHospital de Conxo-CHUS, Santiago de Compostela dClinic University Hospital, Valladolid eBlood and Tissue Bank, Barcelona fRegional Transfusion Center, Madrid gCentro de Hemoterapia de Castilla-León, Valladolid hHospital Miguel Servet, Zaragoza iHospital Clínico Universitario Lozano Blesa, Zaragoza jUniversity Clinic kComplejo Hospitalario, Pamplona lCentro Sanitario Sandoval, Madrid mCristal-Piñor Hospital, Orense nGeneral Hospital, Alicante oHospital Virgen del Rocío, CIBERESP, Seville pRio Ortega Hospital, Valladolid qLa Paz University Hospital, Autonomous University, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000001527DOI Listing
July 2017
171 Reads
5.554 Impact Factor

Obituary: HIV/AIDS researcher Mark Wainberg passed away.

AIDS Rev 2017 Apr - Jun;19(2):115

Infectious Diseases Department, La Paz University Hospital, Madrid, Spain.

View Article

Download full-text PDF

Source
July 2017
19 Reads
3.790 Impact Factor

HIV type 2 epidemic in Spain: challenges and missing opportunities.

AIDS 2017 06;31(10):1353-1364

aPuerta de Hierro Research Institute, Madrid bHospital de Poniente, Almeria cHospital Vall d'Hebrón, Barcelona dCorporación Sanitaria Parc Taulí, Sabadell eSon Espases Hospital, Palma de Mallorca fHospital Marqués de Valdecilla, Santander gFundación Jiménez Díaz, Madrid hGeneral Hospital, Alicante iLa Paz University Hospital & Autonomous University, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000001485DOI Listing
June 2017
166 Reads
2 Citations
5.554 Impact Factor

Transmission of Multi-Drug Resistant HIV-1 Despite Antiretroviral Prophylaxis.

Authors:
Vicente Soriano

AIDS Rev 2017 Jan-Mar;19(1):54-55

La Paz University Hospital, Autonomous University, Madrid, Spain.

View Article

Download full-text PDF

Source
March 2017
15 Reads
1 Citation
3.790 Impact Factor

Hepatitis C virus resistance to the new direct-acting antivirals.

Expert Opin Drug Metab Toxicol 2016 Oct 18;12(10):1197-209. Epub 2016 Jul 18.

a Infectious Diseases Unit , IdiPAZ & La Paz University Hospital , Madrid , Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17425255.2016.1209484DOI Listing
October 2016
18 Reads
8 Citations
2.831 Impact Factor

Non-Human Cancers in AIDS Patients.

AIDS Rev 2015 Oct-Dec;17(4):238-9

Infectious Diseases Unit. La Paz University Hospital. Madrid, Spain.

View Article

Download full-text PDF

Source
September 2016
24 Reads
3.790 Impact Factor

Relationship of TRIM5 and TRIM22 polymorphisms with liver disease and HCV clearance after antiviral therapy in HIV/HCV coinfected patients.

J Transl Med 2016 09 2;14:257. Epub 2016 Sep 2.

Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III (Campus Majadahonda), Carretera Majadahonda- Pozuelo, Km 2.2, 28220, Majadahonda, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12967-016-1005-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5010694PMC
September 2016
57 Reads
3 Citations
3.930 Impact Factor

The Burden of Neglected HIV-2 and HTLV-1 Infections in Spain.

AIDS Rev 2015 Oct-Dec;17(4):212-9

Infectious Diseases Unit, La Paz University Hospital IdiPAZ, Madrid, Spain.

View Article

Download full-text PDF

Source
September 2016
16 Reads
2 Citations
3.790 Impact Factor

Short article: Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b study.

Eur J Gastroenterol Hepatol 2016 Aug;28(8):923-6

aJ.W. Goethe University Hospital, Frankfurt am Main bBoehringer Ingelheim Pharma GmbH & Co. KG, Biberach cBoehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany dThe Liver Institute at Methodist Dallas Medical Center, Dallas eCentral Texas Clinical Research, Austin, Texas fNorthwest Indiana Center for Clinical Research, Valparaiso, Indiana gScripps Clinic, La Jolla, California hBoehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut, USA iHospital Carlos III, Madrid jHospital Universitario Valle de Hebrón and CIBERehd del Instituto Carlos III, Barcelona, Spain kUniversity Clinic for Visceral Surgery and Medicine, University of Bern, Bern, Switzerland lAustin Health, Heidelberg, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MEG.0000000000000649DOI Listing
August 2016
50 Reads
2.152 Impact Factor

Is HIV still a special population for the treatment of hepatitis C?

AIDS 2016 07;30(12):2001-3

aDepartment of Medicine, Division of Infectious Diseases, Owen Clinic, University of California at San Diego, San Diego, California, USA bInfectious Diseases Unit, La Paz University Hospital, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000001135DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4955702PMC
July 2016
14 Reads
2 Citations
5.554 Impact Factor

Prevention and management of treatment failure to new oral hepatitis C drugs.

Expert Opin Pharmacother 2016 Jun 9;17(9):1215-23. Epub 2016 May 9.

b Infectious Diseases Unit , La Paz University Hospital , Madrid , Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2016.1182156DOI Listing
June 2016
49 Reads
7 Citations
3.534 Impact Factor

Hypoglycemia in a diabetic patient during hepatitis C therapy.

Hepatology 2016 06 26;63(6):2065-6. Epub 2015 Nov 26.

Department of Internal Medicine, Puerta de Hierro Research Institute, Majadahonda, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.28137DOI Listing
June 2016
17 Reads
2 Citations
11.055 Impact Factor

SOLAR-2: the sun also rises for cirrhotics.

Lancet Infect Dis 2016 06 18;16(6):624-625. Epub 2016 Feb 18.

Infectious Diseases Unit, La Paz University Hospital, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1473-3099(16)00079-7DOI Listing
June 2016
14 Reads
1 Citation
22.433 Impact Factor

Dual antiviral therapy for HIV and hepatitis C - drug interactions and side effects.

Expert Opin Drug Saf 2015 28;14(9):1421-34. Epub 2015 Jul 28.

a 1 La Paz University Hospital, Infectious Diseases Unit , Madrid, Spain +34 91 7277000 ;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14740338.2015.1073258DOI Listing
May 2016
29 Reads
3 Citations
2.911 Impact Factor

Short Communication: CXCL12 rs1029153 Polymorphism Is Associated with the Sustained Virological Response in HIV/Hepatitis C Virus-Coinfected Patients on Hepatitis C Virus Therapy.

AIDS Res Hum Retroviruses 2016 Mar 1;32(3):226-31. Epub 2015 Dec 1.

2 Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III , Majadahonda, Madrid, Spain .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/AID.2015.0223DOI Listing
March 2016
42 Reads
2.330 Impact Factor

Caution with new oral hepatitis C drugs.

AIDS Rev 2015 Apr-Jun;17(2):121-2

La Paz University Hospital & IdiPAZ, Madrid, Spain.

View Article

Download full-text PDF

Source
February 2016
11 Reads
3.790 Impact Factor

Prioritization of new oral hepatitis C therapies for HIV patients.

AIDS Rev 2015 Jan-Mar;17(1):65-7

La Paz University Hospital, Madrid, Spain.

View Article

Download full-text PDF

Source
November 2015
9 Reads
3.787 Impact Factor

Rate and predictors of serum HCV-RNA >6 million IU/mL in patients with chronic hepatitis C.

J Clin Virol 2015 Oct 13;71:63-6. Epub 2015 Aug 13.

Infectious Diseases Unit, La Paz University Hospital, Madrid, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jcv.2015.08.001DOI Listing
October 2015
55 Reads
3.020 Impact Factor

Extrahepatic comorbidities associated with hepatitis C virus in HIV-infected patients.

Curr Opin HIV AIDS 2015 Sep;10(5):309-15

aHospital Universitario La Paz bInstituto de Investigación Sanitaria La Paz cHospital General Universitario Gregorio Marañón dInstituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/co-hivandaids/2015/09000/Extrah
Web Search
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/COH.0000000000000175DOI Listing
September 2015
33 Reads
9 Citations
4.680 Impact Factor

RNA viruses at the forefront of human infections - HIV, hepatitis C, and now Ebola.

AIDS Rev 2014 Oct-Dec;16(4):246-7

Infectious Diseases Unit, La Paz Hospital & Autonomous University, Madrid, Spain.

View Article

Download full-text PDF

Source
August 2015
9 Reads
3.790 Impact Factor

Update of the DHHS antiretroviral treatment guidelines.

Authors:
Vincent Soriano

AIDS Rev 2014 Apr-Jun;16(2):117-8

Internal Medicine & Infectious Diseases, La Paz University Hospital, Madrid, Spain.

View Article

Download full-text PDF

Source
April 2015
26 Reads
3.787 Impact Factor

TLR3 polymorphisms are associated with virologic response to hepatitis C virus (HCV) treatment in HIV/HCV coinfected patients.

J Clin Virol 2015 Apr 9;65:62-7. Epub 2015 Feb 9.

Unidad de Infección viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jcv.2015.02.004DOI Listing
April 2015
41 Reads
1 Citation
3.020 Impact Factor

Gene therapy for HIV infection.

Expert Opin Biol Ther 2015 Mar 17;15(3):319-27. Epub 2014 Oct 17.

Puerta de Hierro Research Institute and University Hospital, Department of Internal Medicine , Majadahonda, Madrid , Spain

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14712598.2015.967208DOI Listing
March 2015
24 Reads
2 Citations
3.743 Impact Factor

HIV-2 and HTLV-1 infections in Spain, a non-endemic region.

AIDS Rev 2014 Jul-Sep;16(3):152-9

Department of Infectious Diseases, Hospital Carlos III, Madrid; Department of Internal Medicine, La Paz University Hospital, Madrid, Spain.

View Article

Download full-text PDF

Source
March 2015
53 Reads
1 Citation
3.790 Impact Factor

Interferon-free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: SOUND-C3, a Phase 2b study.

Liver Int 2015 Feb 16;35(2):417-21. Epub 2014 Oct 16.

J. W. Goethe University Hospital, Frankfurt am Main, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/liv.12693DOI Listing
February 2015
55 Reads
6 Citations
4.850 Impact Factor

Dolutegravir for the treatment of HIV-2 infection.

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology

http://europepmc.org/abstract/med/25728072

View Article
January 2015
7 Reads

Immediate hypersensitivity to heparins: a cross-reactivity study.

J Investig Allergol Clin Immunol 2014 ;24(5):367-8

View Article

Download full-text PDF

Source
November 2014
5 Reads
2.642 Impact Factor

PPARγ2 Pro12Ala polymorphism is associated with sustained virological response in HIV/HCV-coinfected patients under HCV therapy.

J Acquir Immune Defic Syndr 2014 Oct;67(2):113-9

*Unidad de Infección viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain; †Unidad de Enfermedades Infecciosas/VIH; Hospital General Universitario "Gregorio Marañón," Madrid, Spain; ‡Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain; §IIS-Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid Spain; and ‖Servicio de Enfermedades Infecciosas, Hospital Carlos III, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAI.0000000000000282DOI Listing
October 2014
56 Reads
2 Citations
4.560 Impact Factor

HIV-2 viral tropism influences CD4+ T cell count regardless of viral load.

J Antimicrob Chemother 2014 Aug 30;69(8):2191-4. Epub 2014 Apr 30.

Hospital Carlos III, Madrid, Spain Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jac/dku119DOI Listing
August 2014
86 Reads
5.313 Impact Factor

[Hepatitis E: an emerging viral disease].

Med Clin (Barc) 2014 Jul 20;143(1):22-4. Epub 2014 Mar 20.

Servicio de Enfermedades Infecciosas, Hospital Carlos III, Madrid, España.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.medcli.2014.01.021DOI Listing
July 2014
11 Reads
1.252 Impact Factor

X4 tropic viruses are on the rise in recent HIV-1 seroconverters in Spain.

AIDS 2014 Jul;28(11):1603-9

aHospital Carlos III bCentro Sanitario Sandoval, Madrid cHospital Conxo-CHUS, Santiago dHospital General, Elche & Universidad Miguel Hernández, Alicante eHospital Rio Hortega, Valladolid fHospital Vall d'Hebron, Barcelona gHospital Universitario Puerta de Hierro & Puerta de Hierro Research Institute, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000000269DOI Listing
July 2014
39 Reads
4 Citations
5.554 Impact Factor

Diagnosis of subclinical atherosclerosis in HIV-infected patients: higher accuracy of the D:A:D risk equation over Framingham and SCORE algorithms.

Eur J Prev Cardiol 2014 Jun 20;21(6):739-48. Epub 2012 Jun 20.

Department of Internal Medicine, Hospital Clínico San Carlos, Madrid, Spain Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2047487312452964DOI Listing
June 2014
82 Reads
9 Citations
2.675 Impact Factor

Dolutegravir, abacavir and lamivudine as HIV therapy.

Expert Opin Pharmacother 2014 May;15(7):1051-7

Hospital Carlos III, Department of Infectious Diseases , Madrid , Spain

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14656566.2014.913023DOI Listing
May 2014
30 Reads
2 Citations
3.534 Impact Factor

[Infections due to human immunodeficiency virus type 2 and human T-lymphotropic viruses in Spain].

Med Clin (Barc) 2014 Apr 6;142(7):323-6. Epub 2013 Sep 6.

Servicio de Enfermedades Infecciosas, Hospital Carlos III, Madrid, España.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.medcli.2013.06.009DOI Listing
April 2014
66 Reads
1.252 Impact Factor

Sustained virological response in HIV/HCV co-infected patients treated with pegylated interferon/ribavirin can be predicted from the overall rate of viral load decline over the first 4 weeks of therapy.

J Infect 2014 Apr 22;68(4):372-7. Epub 2013 Nov 22.

Unit of Infectious Diseases, Instituto Maimonides de Investigación Biomedica de Córdoba (IMIBIC), Hospital Universitario Reina Sofia, Cordoba, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jinf.2013.11.009DOI Listing
April 2014
33 Reads
2 Citations
4.441 Impact Factor

A polymorphism linked to RRAS, SCAF1, IRF3 and BCL2L12 genes is associated with cirrhosis in hepatitis C virus carriers.

Liver Int 2014 Apr 16;34(4):558-66. Epub 2013 Oct 16.

Unidad de Enfermedades Infecciosas y Microbiología, Hospital Universitario de Valme, Sevilla, Spain; Instituto de Biomedicina de Sevilla (IBIS), Sevilla, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/liv.12330DOI Listing
April 2014
26 Reads
4.850 Impact Factor

Insulysin

HANDBOOK OF PROTEOLYTIC ENZYMES, VOLS 1 AND 2, 3RD EDITION

https://publons.com/publon/18210160/

View Article
2013
2 Reads

Variations at multiple genes improve interleukin 28B genotype predictive capacity for response to therapy against hepatitis C infection.

AIDS 2013 Nov;27(17):2715-24

aUnit of Infectious Diseases and Microbiology, Hospital Universitario de Valme bInstituto de Biomedicina de Sevilla (IBiS), Seville cImmunogenetics Unit, Faculty of Sciences, Universidad de Jaén, Jaen dUnit of Infectious Diseases, Hospital Universitario Reina Sofía, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Cordoba eDepartment of Infectious Diseases, Hospital Carlos III, Madrid fUnit of Infectious Diseases, Hospital Juan Ramón Jiménez. Huelva, Spain.

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/aidsonline/2013/11130/Variation
Web Search
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/01.aids.0000432459.36970.a9DOI Listing
November 2013
89 Reads
3 Citations
5.554 Impact Factor

The changing epidemiology of liver disease in HIV patients.

AIDS Rev 2013 Jan-Mar;15(1):25-31

Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain.

View Article

Download full-text PDF

Source
http://www.aidsreviews.com/files/2013_15_1_025-031.pdf
Web Search
November 2013
48 Reads
3.787 Impact Factor

Hepatitis C virus genotype 4 in Southern and Central Spain does not originate from recent foreign migration waves.

J Med Virol 2013 Oct 16;85(10):1734-40. Epub 2013 Jul 16.

Unit of Infectious Diseases and Microbiology, Hospital Universitario de Valme, Seville, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jmv.23657DOI Listing
October 2013
27 Reads
3 Citations
2.350 Impact Factor

Antiretroviral drug-related toxicities - clinical spectrum, prevention, and management.

Expert Opin Drug Saf 2013 Sep 4;12(5):697-707. Epub 2013 Jun 4.

Hospital Carlos III, Department of Infectious Diseases, C/Sinesio Delgado 10, Madrid, 28029, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14740338.2013.806480DOI Listing
September 2013
13 Reads
6 Citations
2.911 Impact Factor

Influence of HIV infection on response to tenofovir in patients with chronic hepatitis B.

AIDS 2013 Sep;27(14):2219-24

aDepartment of Infectious Diseases, Hospital Carlos III bHospital Conxo-CHUS, Santiago de Compostela cInibic-Complexo Hospitalario Universitario, A Coruña dCentro Sanitario Sandoval, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0b013e328362fe42DOI Listing
September 2013
39 Reads
3 Citations
5.554 Impact Factor

[Healthcare resources restrictions and human immunodeficiency virus infection].

Med Clin (Barc) 2013 Aug 26;141(3):114-5. Epub 2013 Mar 26.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.medcli.2013.01.034DOI Listing
August 2013
14 Reads
1 Citation
1.252 Impact Factor

Chronic hepatitis E in HIV patients: rapid progression to cirrhosis and response to oral ribavirin.

Clin Infect Dis 2013 Aug 10;57(3):465-8. Epub 2013 Apr 10.

Unit of Infectious Diseases and Microbiology, Hospital Universitario de Valme, Seville, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/cid/cit224DOI Listing
August 2013
26 Reads
12 Citations
8.890 Impact Factor

Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response.

J Infect 2013 Jul 28;67(1):59-64. Epub 2013 Mar 28.

Unit of Infectious Diseases and Microbiology, Hospital Universitario de Valme, Avenida de Bellavista S/N, Seville, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jinf.2013.03.010DOI Listing
July 2013
29 Reads
3 Citations
4.441 Impact Factor

Emerging viral infections‑-a potential threat for blood supply in the 21st century.

AIDS Rev 2012 Oct-Dec;14(4):279-89

Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain.

View Article

Download full-text PDF

Source
June 2013
27 Reads
3 Citations
3.790 Impact Factor

Endothelial dysfunction in HIV infection--the role of circulating endothelial cells, microparticles, endothelial progenitor cells and macrophages.

AIDS Rev 2012 Oct-Dec;14(4):223-30

Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain.

View Article

Download full-text PDF

Source
June 2013
11 Reads
11 Citations
3.790 Impact Factor

Liver stiffness predicts liver-related complications and mortality in HIV patients with chronic hepatitis C on antiretroviral therapy.

AIDS 2013 Apr;27(7):1129-34

Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0b013e32835e063fDOI Listing
April 2013
29 Reads
9 Citations
5.554 Impact Factor